EMA CHMP recommends Moderna's Covid-19 booster for children – Pharmaceutical Technology

A Phase II/III trial of mRNA-1273.214 as a booster and initial regimen in children aged six months to five years is progressing.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting variation to the marketing authorization (MA) for Moderna’s Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214) booster for usage in children aged six to 11 years.
The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination.
The EMA positive opinion is based on clinical findings of mRNA.1273.214, a bivalent Omicron-targeting Covid-19 vaccine of the company.
Moderna’s paediatric application is based on clinical trial booster findings for Spikevax, the company’s original vaccine.
The application also comprised results data from a 25μg booster vaccine given to children of this age group following an initial vaccine regimen with Moderna’s Covid-19 vaccine.
Additionally, the application included findings from a Phase II/III clinical trial of mRNA-1273.214.
According to the data from Phase II/III trials reported in November this year, the company’s bivalent Omicron-targeting booster candidates, mRNA-1273.214 and mRNA-1273.222, showed to induce an antibody response superior to a booster dose of a prototype vaccine against Omicron (BA.4-BA.5), mRNA-1273.
Compared to the original strain, these vaccines met non-inferiority immunogenicity criteria.
At present, a Phase II/III trial of mRNA-1273.214 for usage as a booster and initial regimen in children aged six months to five years is progressing. 
Preliminary data from this trial is anticipated early next year.
Moderna CEO Stéphane Bancel said: “The recommendation to authorise the use of a booster dose of mRNA-1273.214 in children ages six-11 is crucial to providing protection against Omicron and the emergence of new variants of concern, which is especially important during the winter period in Europe when respiratory diseases are on the rise. 
“We are grateful to the CHMP for their review of our submission and look forward to an authorisation decision from the European Commission.”
In September this year, the EMA accepted the company’s submission for a Conditional Marketing Authorization for a 50µg dose of mRNA-1273.222 in adults aged 12 years and above.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
The leading site for news and procurement in the pharmaceutical industry
Powered by Pharma Tech Logo
© Verdict Media Limited 2022